Cait Lamberton of the Wharton School weighed in on how the FDA’s recommendation to pause distribution of Johnson & Johnson’s COVID-19 vaccine will affect the company’s reputation. “I don’t think this is going to be a huge dagger in J&J’s heart,” she said. “They’ve seen this stuff before. They’ve had plenty of product crises.”
https://www.wsj.com/articles/covid-19-vaccine-issues-present-new-challenge-for-j-j-11618338625 The Wall Street Journal